Cost ‐effectiveness of omalizumab for the treatment of Chronic Spontaneous Urticaria

ConclusionsOmalizumab is cost‐effective compared to SoC. The outcomes of this study were used to establish omalizumab as third‐line treatment in the Dutch treatment guidelines for CSU.This article is protected by copyright. All rights reserved.

Source: British Journal of Dermatology - February 24, 2018 Category: Dermatology Authors: T. A. Kanters, H. B. Thio, L. Hakkaart Tags: Original Article Source Type: research